PET-OSAEffects of Continuous Positive Airway Pressure Therapy on Myocardial Energetics and Sympathetic Nerve Function in Patients With Heart Failure and Obstructive Sleep Apnea.
Positron Emission Tomography
Apnée+10
+ Maladies Cardiovasculaires
+ Maladies Cardiaques
Étude thérapeutique
Résumé
Date de début de l'étude : 1 juillet 2005
Date à laquelle le premier participant a commencé l'étude.OSA and heart failure (HF) are states of increased afterload, metabolic demand and sympathetic nervous system(SNS) activation. In patients with OSA and HF, CPAP initially may reduce LV stroke volume(SV) but subsequently improves LV function. This may relate to an early beneficial effect on myocardial energetics through early reduction in metabolic demand that subsequently leads to improved efficiency of LV contraction. However, it is not clear whether CPAP favourably affects cardiac energetics. Any such benefit may also relate to reduced SNS activation with CPAP therapy. However its effect on myocardial SN function is also not well studied. We propose to evaluate the temporal effect of CPAP on daytime 1) oxidative metabolism; 2) the WMI as an estimate of mechanical efficiency; 3) myocardial SN pre-synaptic function; and 4) HR variability in patients with OSA and HF. We will also determine whether these parameters are altered compared to a group of patients with HF without OSA. In conjunction with echocardiographic measures of LV stroke work, PET derived \[11C\]acetate kinetics will be used as a measure of oxidative metabolism, to determine the work metabolic index (WMI). \[11C\]HED retention will be used to measure cardiac SN pre-synaptic function. HYPOTHESES Primary Hypotheses: In patients with chronic stable HF and OSA, 6-8 weeks' of CPAP demonstrates: 1. beneficial effects on daytime myocardial metabolism leading to a reduction in the rate of oxidative metabolism as measured by \[11C\]acetate kinetics using PET imaging; 2. improvement in energy transduction from oxidative metabolism to stroke work as measured by an increase in the daytime work-metabolic index. Secondary Hypotheses: In patients with chronic stable heart failure and OSA, 1. CPAP leads to an early (1 week'') reduction in daytime oxidative metabolism that precedes the improvement in work-metabolic index, indicating an early energy sparing effect; 2. CPAP leads to i) an increase in daytime myocardial SN pre-synaptic function as measured by increased \[11C\]HED retention on PET imaging, and ii) a parallel decrease in sympathetic and increase in vagal modulation of sino-atrial discharge (i.e. heart rate (HR) variability) 3. there is impaired daytime myocardial oxidative metabolism, work-metabolic index, and myocardial sympathetic nerve function compared to patients with heart failure without OSA. 'original protocol indicated 1 month follow up but was changed to 6-8 weeks in order to accommodate patient logistics and imaging centre scheduling. ''Logistics did not permit all patients to complete 1 week scan.
Protocole
Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.67 participants à inclure
Nombre total de participants que l'essai clinique vise à recruter.Traitement
Éligibilité
Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.Tout sexe
Le sexe biologique des participants éligibles à s'inscrire.À partir de 18 ans
Tranche d'âge des participants éligibles à participer.Volontaires sains non autorisés
Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.Conditions
Pathologie
Critères
Inclusion Criteria: * systolic LV dysfunction (LVEF\<40%; by echocardiography, radionuclide or contrast ventriculography) * symptoms of HF: NYHA Class II to III * stable condition with optimally tolerated medical therapy, unchanged for \> 4 weeks * Obstructive sleep apnea (OSA) diagnosed on nocturnal polysomnogram with an apnea/hypopnea index (AHI) \>15 events/hr and a predominantly obstructive pattern(more than 80% of events being obstructive in nature)OR * no OSA: defined as AHI\<5 (control subjects) will be matched with the OSA group for gender, age + 5 years, ejection fraction (EF) +5%, drug therapy and etiology of HF (ischemic or non-ischemic) * willingness to receive CPAP therapy * informed consent Exclusion Criteria: * unstable angina or recent myocardial infarction (MI) (\<4 weeks prior) * severe valvular dysfunction * requirement for revascularization * a permanent pacemaker * atrial fibrillation * significant ventricular arrhythmia or sinus node dysfunction * life expectancy less than 1 year due to other co-morbidity * significant restrictive and obstructive lung disease * concomitant treatment or use of: tricyclic antidepressants, cocaine or drugs which may alter catecholamine uptake; or hypnotic, benzodiazepine, selective serotonin reuptake inhibitors(SSRI), neuroleptic, narcotic or other medications which may alter sleep or sleep-disordered breathing * central sleep apnea * other primary sleep disorder (i.e. periodic limb movement with arousal \>5 events/hr, narcolepsy, rapid eye movement (REM) behaviour disorder) * requiring supplemental oxygen therapy at night * debilitating daytime somnolence (indicating clear-cut indication for CPAP therapy) * a previous cardiac transplant * a large transmural scar defined on previous perfusion imaging(severe resting perfusion defect (\<50% uptake) occupying \>25% of the LV)148-150 * age \< 18 years * pregnant or breast-feeding
Plan de l'étude
Découvrez tous les traitements administrés dans cette étude, leur description détaillée et ce qu'ils impliquent.3 groupes d'intervention sont désignés dans cette étude
Cette étude ne comporte pas de groupe placebo.
Groupes de traitement
Groupe I
Comparateur actifGroupe II
Comparateur actifGroupe III
Objectifs de l'étude
Objectifs principaux
Objectifs secondaires
Centres d'étude
Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.Cette étude comporte 1 site